Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou 310000, China.
Int J Environ Res Public Health. 2022 Nov 29;19(23):15939. doi: 10.3390/ijerph192315939.
(1) Objectives: This study evaluated the clinical outcomes of dental implants placed in previously failed sites and discussed the risk factors that mattered in reimplantation. (2) Methods: All the cases by one specific implantologist during his first five years of clinical practice were screened, with a focus on those who received reimplantation. The clinical outcomes were assessed, including the implant survival, peri-implant health, and patients' satisfaction. (3) Results: 28 patients (31 implants) were recorded as failures from 847 patients (1269 implants), with a 2.4% overall failure rate at the implant level, of whom 19 patients (21 implants) received reimplantation treatment. After a mean follow-up of 33.7 ± 10.1 months (95% CI 29.1-38.3 months), 20 implants remained functional, but 1 implant revealed a secondary early failure, indicating a 95.2% overall survival rate. The mean probing depth (PD), modified sulcus bleeding index (mSBI), and marginal bone loss (MBL) of the surviving reinserted implants were 2.7 ± 0.6 mm (95% CI 2.5-3.0 mm), 0.7 ± 0.5 (95% CI 0.5-1.0), and 0.5 ± 0.6 mm (95% CI 0.3-0.8 mm), respectively. Embedded healing occurred more frequently in the reinserted implants than in the primary implants ( = 0.052). The patients' satisfaction suffered from implant failure, but a successful reimplantation could reverse it with close doctor-patient communication. (4) Conclusions: Reimplantation treatment was recommended, based on a thorough evaluation and consideration of the risk factors combined with effective communication with the patients.
(1) 目的：本研究评估了在先前失败部位植入的牙种植体的临床效果，并讨论了再植入的相关风险因素。(2) 方法：筛选出一位特定种植医生在其临床实践的头五年中所有的病例，重点关注那些接受再植入的病例。评估了临床结果，包括种植体的存活率、种植体周围健康状况和患者满意度。(3) 结果：在 847 名患者（1269 枚种植体）中，有 28 名患者（31 枚种植体）被记录为失败病例，总体种植体失败率为 2.4%，其中 19 名患者（21 枚种植体）接受了再植入治疗。在平均 33.7 ± 10.1 个月（95%CI：29.1-38.3 个月）的随访后，20 枚种植体仍有功能，但 1 枚种植体出现继发性早期失败，总存活率为 95.2%。再植入种植体的平均探诊深度（PD）、改良龈沟出血指数（mSBI）和边缘骨丧失（MBL）分别为 2.7 ± 0.6mm（95%CI：2.5-3.0mm）、0.7 ± 0.5（95%CI：0.5-1.0）和 0.5 ± 0.6mm（95%CI：0.3-0.8mm）。再植入种植体的嵌入式愈合发生率高于初次种植体（ = 0.052）。患者的满意度因种植体失败而受到影响，但通过密切的医患沟通，成功的再植入可以改善这种情况。(4) 结论：在对风险因素进行全面评估和考虑，并与患者进行有效沟通的基础上，建议进行再植入治疗。
